CR20130288A - Comprimido farmacéutico de liberación controlada para administración oral - Google Patents

Comprimido farmacéutico de liberación controlada para administración oral

Info

Publication number
CR20130288A
CR20130288A CR20130288A CR20130288A CR20130288A CR 20130288 A CR20130288 A CR 20130288A CR 20130288 A CR20130288 A CR 20130288A CR 20130288 A CR20130288 A CR 20130288A CR 20130288 A CR20130288 A CR 20130288A
Authority
CR
Costa Rica
Prior art keywords
oral administration
controlled release
compressed pharmaceutical
pharmaceutical controlled
compressed
Prior art date
Application number
CR20130288A
Other languages
English (en)
Inventor
Arroyo Héctor Senosiain
Paniagua María Angélica Arzola
Hernández Gustavo Barranco
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46245166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130288(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of CR20130288A publication Critical patent/CR20130288A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN TIENE SU APLICACIÓN EN EL CAMPO FARMACÉUTICO, ESPECIALMENTE EN EL DE COMBINACIÓN Y COMPOSICIÓN FARMACÉUTICAS QUE COMPRENDEN UN INHIBIDOR DE LA LIPASA Y UNA FITOALEXINA Y VEHICULOS O EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES.-
CR20130288A 2010-12-17 2013-06-13 Comprimido farmacéutico de liberación controlada para administración oral CR20130288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2010014153A MX2010014153A (es) 2010-12-17 2010-12-17 Comprimido farmaceutico de liberacion controlada para administracion oral.
PCT/IB2011/055720 WO2012080984A2 (es) 2010-12-17 2011-12-16 Comprimido farmacéutico de liberación controlada para administración oral

Publications (1)

Publication Number Publication Date
CR20130288A true CR20130288A (es) 2013-08-13

Family

ID=46245166

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130288A CR20130288A (es) 2010-12-17 2013-06-13 Comprimido farmacéutico de liberación controlada para administración oral

Country Status (11)

Country Link
BR (1) BR112013014963A2 (es)
CL (1) CL2013001707A1 (es)
CO (1) CO6721021A2 (es)
CR (1) CR20130288A (es)
DO (1) DOP2013000136A (es)
EC (1) ECSP13012766A (es)
GT (1) GT201300154A (es)
MX (1) MX2010014153A (es)
PE (1) PE20140675A1 (es)
RU (1) RU2603469C2 (es)
WO (1) WO2012080984A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016058813A1 (en) 2014-10-16 2016-04-21 Koninklijke Philips N.V. Aligning a patient within an mr scanner

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
AU2002358270A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same

Also Published As

Publication number Publication date
RU2603469C2 (ru) 2016-11-27
BR112013014963A2 (pt) 2016-09-13
RU2013127408A (ru) 2015-01-27
MX2010014153A (es) 2012-06-18
CL2013001707A1 (es) 2014-01-10
ECSP13012766A (es) 2013-09-30
PE20140675A1 (es) 2014-06-25
DOP2013000136A (es) 2013-10-15
CO6721021A2 (es) 2013-07-31
WO2012080984A3 (es) 2012-08-16
WO2012080984A2 (es) 2012-06-21
GT201300154A (es) 2014-05-07

Similar Documents

Publication Publication Date Title
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
ECSP13012534A (es) Composición farmacéutica
CL2013003145A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre.
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
CR20110110A (es) Composicion farmaceutica
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
CL2013003577A1 (es) Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas.
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
ECSP12011585A (es) Compuestos y composiciones para eltratamiento de enfermedades parasitarias
SV2010003744A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
MX2015016627A (es) Vacuna para la malaria.
WO2011101863A3 (en) Extended release pharmaceutical compositions of lacosamide
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
BR112014021068A8 (pt) inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
CL2013000335A1 (es) Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension.
ES2422877B1 (es) Combinación y composición para el tratamiento de obesidad
CR20130288A (es) Comprimido farmacéutico de liberación controlada para administración oral
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad